Scribe Therapeutics (SCTX) Stock Analysis

What Scribe Therapeutics does

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

Key metrics

ETFs linked to SCTX

Broad-market and Healthcare sector ETFs an investor holding Scribe Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SCTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Scribe Therapeutics?

Scribe Therapeutics trades under the ticker SCTX on NASDAQ.

Which exchange is SCTX listed on?

SCTX is listed on NASDAQ.

What sector does Scribe Therapeutics operate in?

Scribe Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SCTX in a portfolio?

PortView shows SCTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.